Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NASDAQ | Common Stock
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally.
The company's marketed product includes AMITIZA (lubiprostone), a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension.
Its product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.
The company is also developing VTS-270, which is in a pivotal Phase 2b/3 trial for the treatment of Niemann-Pick Disease Type C1.
Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Sep 30, 17 | 0.27 Decreased by -3.57% | 0.25 Increased by +8.00% |
| Jun 30, 17 | 0.28 Increased by +21.74% | 0.27 Increased by +3.70% |
| Mar 31, 17 | 0.23 | 0.27 Decreased by -14.81% |
| Dec 31, 16 | 0.68 | 0.48 Increased by +41.67% |
| Sep 30, 16 | 0.28 | 0.27 Increased by +3.70% |
| Jun 30, 16 | 0.23 | 0.22 Increased by +4.55% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 17 | 61.27 M Increased by +5.86% | 10.37 M Increased by +28.13% | Increased by +16.92% Increased by +21.03% |
| Jun 30, 17 | 59.90 M Increased by +15.29% | -181.17 M Decreased by -21.67 K% | Decreased by -302.47% Decreased by -18.79 K% |
| Mar 31, 17 | 56.28 M Increased by +19.22% | 4.62 M Increased by +213.98% | Increased by +8.22% Increased by +195.60% |
| Dec 31, 16 | 73.02 M Increased by +31.89% | 15.28 M Increased by +50.57% | Increased by +20.93% Increased by +14.16% |
| Sep 30, 16 | 57.87 M Increased by +73.02% | 8.09 M Increased by +11.83% | Increased by +13.98% Decreased by -35.37% |
| Jun 30, 16 | 51.95 M Increased by +48.93% | -832.00 K Decreased by -108.69% | Decreased by -1.60% Decreased by -105.83% |
| Mar 31, 16 | 47.21 M Increased by +60.14% | -4.06 M Decreased by -163.31% | Decreased by -8.59% Decreased by -139.54% |
| Dec 31, 15 | 55.37 M Increased by +46.64% | 10.15 M Increased by +9.36% | Increased by +18.33% Decreased by -25.42% |